<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00201396</url>
  </required_header>
  <id_info>
    <org_study_id>T1303</org_study_id>
    <nct_id>NCT00201396</nct_id>
  </id_info>
  <brief_title>A Multicenter Trial Comparing Induction C/T Followed by CCRT v.s. CCRT Alone in Stage IV Nasopharyngeal Carcinoma</brief_title>
  <official_title>A Multicenter Phase III Trial Comparing Induction Chemotherapy Followed by Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Stage IV Nasopharyngeal Carcinoma (NPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Health Research Institutes, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tri-Service General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chung Shan Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changhua Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chi Mei Medical Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaohsiung Medical University Chung-Ho Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaohsiung Veterans General Hospital.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Health Research Institutes, Taiwan</source>
  <brief_summary>
    <textblock>
      Investigate the effect of induction MEPFL chemotherapy followed by concurrent
      chemoradiotherapy (CCRT) on the disease control and survival in treatment of patients with
      advanced NPC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale of induction chemotherapy:

      Distant metastasis is the major cause of treatment failure and deaths in patients with
      loco-regionally advanced NPC.

      Concurrent chemoradiotherapy may prolong survivals for patients with advanced NPC, but it is
      still flawed by high incidence of distant metastasis.

      Induction chemotherapy with MEPFL has been shown to reduce the incidence of distant
      metastasis in a Phase II study.

      Induction chemotherapy plus concurrent chemoradiotherapy may improve the survival of patients
      with advanced NPC.

      Objectives:

      Investigate the effect of induction MEPFL chemotherapy followed by concurrent
      chemoradiotherapy (CCRT) on the disease control and survival in treatment of patients with
      advanced NPC.

      Study design:

      This is a randomized, multi-center Phase III study. Patients will be randomized to CCRT with
      or without the MEPFL induction chemotherapy.

      Type and number of patients:

      Patients with stage IVA (T4) and/or IVB (N3) but without distant metastasis will be enrolled.
      A total of up to 480 patients will be randomized to detect an improvement of median overall
      survival from 5.8 to 8.7 years, with an a=0.05 and power of 0.8 using a two-sided logrank
      test with one interim analysis.

      Treatment schedule:

      Induction chemotherapy and CCRT:

      Arm A: Weekly cisplatin concurrently with radiotherapy Arm B: Induction MEPFL three cycles
      followed with weekly cisplatin concurrently with radiotherapy.

      Study endpoints:

      The primary endpoint is the disease-free survival that will be calculated as the duration
      between the date of randomization and the date of recurrence of NPC at any site including
      persistent disease after +induction chemotherapy/CCRT, or death from any cause (failed), or
      the date of withdrawal (last contact date, censored), or the scheduled data analysis date
      (censored).( revised 8/27/2004)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is the disease-free survival.</measure>
    <time_frame>10 years</time_frame>
    <description>follow up for 2 years after off study treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoints include overall survival and tumor response rate.</measure>
    <time_frame>10 years</time_frame>
    <description>follow up for 2 years after off study treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">480</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>A arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CCRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction/CCRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>CCRT</intervention_name>
    <description>Radiation with weekly Cisplatin</description>
    <arm_group_label>A arm</arm_group_label>
    <arm_group_label>B arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin C,Epirubicin,Cisplatin,5-Fluorouracil,Leucovorin</intervention_name>
    <description>Induction C/T + CCRT</description>
    <arm_group_label>B arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proved nasopharyngeal carcinoma.

          -  T4NxM0 or TxN3M0 disease by UICC/AJCC 1997 staging system. (30)

          -  Eastern Cooperative Oncology Group performance status &lt; 2.

          -  A leukocyte count ≥3750/mL, Hb ≥ 10 g/dL, and a platelet count ≥100,000/mL.

          -  A serum bilirubin level &lt; 1.5 mg/dL, serum creatinine level &lt; 1.6 mg/dL or creatinine
             clearance &gt; 60 mL/min.

          -  Age less than 70 years old

          -  An informed consent signed.

        Exclusion Criteria:

          -  Evidence of metastatic disease.

          -  Presence of another malignancy other than treated squamous/basal cell carcinoma of the
             skin.

          -  Presence of uncontrolled hypertension, poorly controlled heart failure.

          -  Presence of active infection.

          -  Patients who have been or are being treated with chemotherapy, radiotherapy,
             immunotherapy, or other experimental therapies.

          -  Women who test positive for pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruey-Long Hong, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taiwan cooperative oncology group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>80708</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>115</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang-Gung Memorial Hospital(Lin-Kou),</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>February 23, 2015</last_update_submitted>
  <last_update_submitted_qc>February 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>A Multicenter Phase III Trial</keyword>
  <keyword>Induction Chemotherapy</keyword>
  <keyword>Concurrent Chemoradiotherapy</keyword>
  <keyword>Stage IV Nasopharyngeal Carcinoma (NPC)</keyword>
  <keyword>randomization</keyword>
  <keyword>disease-free survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

